AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in ...
Monthly Prescribing Reference10h
Acalabrutinib Gets Priority Review for Previously Untreated Mantle Cell Lymphoma
Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...
TheDerrick.com10h
Malaysian and Pakistani prime ministers agree to boost trade and economic ties
The prime ministers of Malaysia and Pakistan have agreed to increase bilateral trade and boost economic ties after talks in ...
Targeted Oncology10h
Acalabrutinib Receives FDA Priority Review in Frontline MCL
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...
TheDerrick.com10h
PFF adds an in-game grading feature to its NFL analysis
Focus changed how many fans followed the NFL by providing grades and advanced statistics to help quantify how every player ...
The Pharma Letter12h
Calquence closer to first-line MCL approval
AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...
Buy15h
TOP NEWS: AstraZeneca's Calquence gets priority review in US
(Alliance News) - AstraZeneca PLC on Thursday said its cancer treatment Calquence obtained priority review by the US Food & Drug Administration for a form of lymphoma.